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Abstract
Background: The misuse of codeine is of increasing concern in a number of countries, particularly as this relates
to over -the-counter pain and cough relief medication, and is also supplied as a prescription medicine. The study
aimed to obtain and analyse the opinions and experience of pharmacy staff with regard to codeine misuse.
Methods: A cross-sectional web-based survey of pharmacy staff’s perspectives on this issue was administered
through professional or regulatory bodies and completed by samples drawn in South Africa (n = 124), Ireland
(n = 464) and the United Kingdom (n = 129).
Results: The majority of participants reported combination codeine-containing products as most popular, but
significantly more pharmacy staff in South Africa reported codeine-containing cough syrups as most commonly
popular (X2 = 122.7(2), p < 0.001). Codeine use was also seen significantly more of a public health problem in South
Africa than in the other two countries (X2 = 7.6(2), p = 0.02). There was no difference across countries in the level of
codeine misuse reported by pharmacy staff. Further findings indicate that professional training and education is
desired, with unequivocal findings for the need for greater codeine control (X2 = 12.0(2), p = 0.002).
Conclusion: In conclusion, there were some inter-country differences, but overall the findings seem to suggest that
pharmacists across all three countries view codeine misuse as a problem among their customers. Recommendations
centre on risk management, surveillance and staff training.
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Background
Global public health and medicines regulatory concerns are
increasingly focused on the issue of the intentional or unin-
tentional misuse of pharmaceutical opioids [1–3]. Misuse
of medicines, including codeine, is defined as ‘the problem-
atic consumption outside of acceptable medical practice or
medical guidelines, when self-medicating at higher doses
and for longer than is advisable, for intoxicating purposes
and when risks and adverse consequences outweigh the
benefits’ [1].
Codeine (3-methylmorphine) is one of the most widely
available and consumed opiates worldwide, and is most
commonly used for its analgesic, antitussive and anti-
diarrhoeal properties [4, 5]. Although viewed as a weak
opiate, it still has the potential for misuse and abuse or
dependence and has a number of associated side effects,
such as sedation, euphoria and constipation [6]. Long
term or high dose use of combination products contain-
ing codeine with ibuprofen or paracetamol can also lead
to a number of side effects [6] such as inflammatory
bowel conditions, nephrotoxicity, hypokalemia, pancrea-
titis, gastric ulcers, gastrointestinal haemorrhage, medi-
cation over-use, headache, depression and paracetamol
hepatotoxicity [7]. Physical tolerance develops over time
and unpleasant withdrawal type physical effects can
occur when usage stops [6, 8].
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While codeine may be prescribed by medical profes-
sionals for management of moderate pain or its antitussive
properties, it is widely available in some countries in over-
the-counter (OTC) preparations, albeit in lower dosages or
combination products, including Ireland, South Africa and
the United Kingdom (UK). This availability is associated
with public lack of awareness of its potential for habit form-
ing use, risk of development of tolerance and dependence
with related health harms particularly relating to excessive
or long-term use [9–12].
Opiate abuse occurs when codeine-containing prod-
ucts are used for recreational and excessive dose pur-
poses as opposed to medical purposes [4], and can lead
to an opioid disorder [13]. Codeine is available to the
public over-the-counter and without a doctor’s prescrip-
tion in a number of countries, which complicates con-
sumer recognition of problem use itself [14–17].
Previous studies have illustrated how individuals with
iatrogenic dependence post-medical use for pain, anxiety
or sleeplessness, may experience ‘blurring’ between
therapeutic and problematic use over time [8, 18].
The regulation of codeine-containing medicines varies
by country, with certain countries such as Australia
recently restricting availability to prescription-only status
following other European countries such as Austria and
Italy [19]. Calls for revised scheduling and enhanced
surveillance and pharmaco-vigilance have been made in
countries where OTC non-prescription misuse of
combination analgesics is rising [20, 21]. A recent qualita-
tive study in South Africa, UK and Ireland indicated that
pharmacist opinions about up-scheduling OTC codeine
are mixed [14]. This is coupled with emerging evidence
that codeine misuse is increasingly becoming an issue in
these countries, with treatment demand data (the number
of people seeking treatment for codeine either as a
primary or secondary drug of choice) starting to show an
increase in trend in all three jurisdictions [19, 22, 23].
Aim of the study
The specific aim of this study was to consider codeine
misuse and the potential control of and management of
codeine in three counties according to pharmacy staff.
Specific objectives included investigating pharmacists’ views
on codeine use as a significant health problem, misuse and
dependence, their level of skills and expertise that can equip
them for dealing with presented codeine misuse and
dependence, and where future training might be helpful.
Methods
Design
The study comprised a cross- sectional survey con-
ducted in the UK, Ireland and South Africa. It was
undertaken as part of a large scale multi-country effort
(CODEMISUSED Project) to investigate codeine use,
Table 1 Codeine Regulations in Ireland, South Africa and the UK
Ireland Irish medicine board.
Guided under the misuse
of drugs act 1977.
Over the counter sales permissible in regulated
pharmacies under supervision of the pharmacists
without prescription Usually in 8 mg/500 and
12.8 mg/500 combination drugs containing
analgesics such as paracetamol and aspirin.
Cannot be visually displayed or advertised to
the consumer.
Patient must be advised on its use at point of sale
Must contain warning of addiction on pack.
Higher strength codeine formulations 15/300, 30/500
of codeine phosphate/paracetamol combinations- are
prescription only medicines.
Codeine is also available combined with Ibuprofen; a
common formulation is 12.8 mg Codeine alongside
200 mg Ibuprofen.
Preparations containing pure codeine (e.g., codeine
phosphate tablets is considered controlled drug (CD)
(Controlled Drug (Possession without authority is illegal).
South
Africa
South African medicines
agency.
Over the counter preparations in combination
with one or more therapeutically active substances,
and containing 20 mg or less of codeine (calculated
as base) per dosage unit, .
Pack sizes sold can contain up to 100 doses.
Sold under supervision of the pharmacists.
Sales of codeine containing products must
be recorded in the pharmacy.
Prescription Only Medication (POM) medicine in doses
up to 20 mg of codeine per dosage unit and are only
available on medical prescription.
United
Kingdom
Medicine and healthcare
products regulatory
authority Controlled under
the Medicine of Drugs Act
1971.
Over the counter sales permissible in regulated
pharmacies under supervision of the pharmacists
without prescription. Usually in 8/500 and
12.8/500 combination drugs containing
analgesics such as paracetamol and aspirin.
1 over the counter Dihydrocodeine product
containing 7.46 mg of active ingredient.
Only 1 pack × 32 tablets allowed per customer
transaction unless sanctioned by the pharmacist.
Can be visually displayed and advertised to the
consumer at the point of sale, under pharmacist
supervision.
Must contain warning of addiction on pack.
Higher strength codeine formulations 15/300, 30/500 of
codeine phosphate/paracetamol combinations are
prescription only medicines (POM). Codeine is also
available combined with Ibuprofen; a common
formulation is 12.8 mg Codeine alongside 200 mg
Ibuprofen.
Preparations containing pure codeine (e.g., codeine
phosphate tablets is considered a controlled drug (CD).
(Possession without authority is illegal).
No longer permitted for use under the age of 18 years
(codeine containing linctus for cough).
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misuse and dependence (see Table 1 for regulatory dif-
ferences between these three countries).
Study population
Eligible subjects were either registered pharmacists or
pharmacy assistants or technicians as regulated by the ap-
propriate pharmaceutical associations in each country. Re-
tail pharmacy staff not involved in the dispensing or sale
of medication were excluded from this study. Participants
were identified by professional/regulatory bodies or phar-
macy trade organisations in each of the three participating
countries: The Pharmaceutical Society of South Africa
(PSSA), the Independent Company Chemist Alliance
(ICCA) in the UK and the Pharmaceutical Society of
Ireland (PSI). The PSSA is an independent professional
body that represents pharmacists and pharmacists’ assis-
tants in South Africa. An estimated 7018 individuals are
registered in South Africa with the PSSA.The ICCA is an
independent body whose members are in the privately
owned regional multiple pharmacy sector. It represents
over 600 pharmacies throughout the United Kingdom of
Great Britain and Northern Ireland. Similarly, the PSI is
an independent statutory body that is charged with, and
accountable for, the effective regulation of pharmacy ser-
vices in Ireland. There are 1843 pharmacies in Ireland reg-
istered with the PSI, with 5280 registered pharmacists and
452 registered pharmaceutical assistants.
Web-based survey instrument
A web-based survey was developed, and the preliminary
questionnaire was sent out to pharmacy and research staff
partners on the CODEMISUSED Project for feedback.
The questionnaire was then revised, and sent to the expert
advisory panel consisting of experts in pharmacology, ad-
diction and pharmacovigilance. The web-based survey
was developed and hosted on a secure website hosted at
the South African Medical Research Council, with only
the lead author (TC) having direct access to the data.
The survey was then pilot-tested among 15 pharma-
cists across the three countries, and the only suggestions
to modify the questionnaire were minor editing issues.
The link to the finalised questionnaire was: http://code-
misused.mrc.ac.za which took participants to the home-
page. This was put online in March 2015.
The final survey had 24 items with each having various
response categories, including ‘yes/no’ responses, op-
tions to select all that apply and open-ended questions.
The survey was divided into four sections on demo-
graphics, codeine misuse as a public health problem and
the impact of this, risk management and innovation.
Questions included participants’ views on their experi-
ences of codeine misuse, and training for dealing with is-
sues as well as recommendations for innovation.
Procedures
Ethics approval was provided by the research ethics
committees of Waterford Institute of Technology in
Ireland; King’s College London in the UK and the South
African Medical Research Council in South Africa.
In South Africa, the PSSA included a link to the online
survey in their annual newsletter. The The director of
PSSA included a link to the survey in the annual news-
letter, which all pharmacist and pharmacist’s assistants
that are registered with the Society receive, to the online
questionnaire for WP4.
In addition, a list of registered pharmacists and pharmacy
assistants were emailed the link to the survey and an infor-
mation letter from an email address especially formulated
for this study. In the UK, members of the ICCA were sent
an information letter and the link to the online survey. In
Ireland the PSI sent out an email to each registered
pharmacist and pharmaceutical assistant requesting them
to complete the survey, as well as the information letter
and the link to the online questionnaire.Participants were
asked to read an information sheet which provided further
details about the aims of the study. Before participants
could progress to participating in the actual survey they
had to tick each box to say that they agreed that they
understand they had read the information sheet, their
participation was voluntary, they understood the study and
that their identity would be kept confidential. Informed
consent was therefore obtained from all individual partici-
pants included in the study.
Data analysis
Quantitative data from the survey was first analysed
using descriptive statistics using SPSS version 23. The
data was then analysed to compare any country differ-
ences. Since the quantitative data was non-normally dis-
tributed, any continuous data was compared by using
the Kruskal-Wallis H statistical test. P-values of pairwise
categorical (yes/no-type) count data were calculated
using Pearson Chi-square test statistics with the excep-
tion of the amount of codeine misused which was
ordinal data (low, medium, high). In this case, the
Linear-by-Linear Association test statistics were used.
Results
There were 464 Irish participants, 123 participants from
South Africa and 129 participants from the UK. Table 2
shows the personal demographics of the participants and
types of pharmacies in which they work. Across sites,
the majority of participants were female and aged
between 20 and 39 years old. There were no significant
differences in the gender breakdown between countries
(X2 = 2.54, df = 2, p = 0.28), but there were significant age
differences (X2 = 27.81, df = 2, p < 0.001). South African
participants reporting a significantly higher average
Carney et al. Substance Abuse Treatment, Prevention, and Policy  (2018) 13:12 Page 3 of 8
number of years in practice than those in Ireland and
the UK (X2 = 42.03, df = 2, p < 0.001).
While the majority of participants reported working in
urban settings, with significant differences noted be-
tween sites (X2 = 11.03, df = 4, p = 0.02). Most were full-
time pharmacists in community/retail pharmacies, with
a small number working in other settings such as aca-
demic or hospital settings, and significant differences be-
tween the three countries (X2 = 8.80, df = 2, p = 0.01).
There were also some significant country differences
between the number of pharmacies close to (within a
3 km radius) the participants’ workplace, (X2 = 53.54,
df = 6, p < 0.001), with seemingly few surrounding
pharmacies in South Africa.
While a small proportion of participants in Ireland (n
= 8, 1.8%) and the UK (n = 1, 0.8%) reported that cough
and cold syrups containing codeine are popular products
sold in their pharmacy, this proportion was significanlty
larger in South Africa (n = 34, 27.9%) (Table 3). In all
three countries combination medication (that is, those
containing codeine together with other ingredients
such as paracetamol and ibuprofen) were mentioned
as being most popular (Ireland: n = 448, 98.2%; South
Africa: n = 88, 72.1%; UK: n = 128, 99.2%), although
this was significantly lower in South Africa (X2 = 122.
7(2), p < 0.001) (see Table 3).
The trade names of popular products containing co-
deine differed between the three countries. The majority
of Irish participants reported that Solpadeine® (n = 355, 76.
7%) and Nurofen Plus® (n = 337, 72.8%) were the most
popular codeine-containing OTC products sold, followed
by Maxilief® (n = 97, 21.0%). In South Africa, participants
Table 2 Demographics of pharmacy staff across the three countries and cross-country comparisons
Demographic Characteristics Ireland (n = 464)
(n,%)
South Africa (n = 123)
(n,%)
UK (n = 129)
(n, %)
Test statistic χ2(df) p-value
Gender
Male 168 (36.2%) 53 (43.1%) 44 (34.1%) 0.28
Female 296 (63.8%) 70 (56.9%) 85 (65.9%) 2.54 (2)
Age
20–39 278 (59.9%) 41 (33.3%) 72 (55.8%) 41.70 (2) < 0.001*
40+ 186 (40.1%) 82 (66.7%) 57 (44.2%)
Number of years in practice: Median (Range) 12 (1–49) 25 (0–49) 15 (1–48) 42.03 (2) < 0.001*
Type of location
Urban 261 (56.3%) 84 (68.3%) 75 (58.6%) 11.03 (4) 0.02*
Rural 99 (21.3%) 17 (13.8%) 17 (13.3%)
Both 102 (22.0%) 21 (17.1%) 36 (28.1%)
Missing 2 1 1
Type of pharmacy
Community/retail 400 (86.2%) 98 (83.1%) 117 (95.1%) 8.80 (2) 0.01*
Others (Academic, Hospital, More than one type of
pharmacy)
61 (13.1%) 24 (16.9%) 10 (4.9)
Missing 3 1 2
Position
Full-time 317 (68.3%) 87 (71.9%) 91 (70.5%) 21.65 (6) < 0.001*
Part-time 57 (12.3%) 4 (3.3%) 16 (12.4%)
Locum 67 (14.4%) 14 (11.6%) 13 (10.1%)
Pharmacy assistant 20 (4.3%) 16 (13.2%) 9 (7.0%)
Nearby pharmacies
0 49 (10.7%) 17 (13.8%) 12 (9.3%) 53.54 (8)
1–5 175 (38.0%) 76 (61.8%) 82 (63.6%) < 0.001*
6–10 140 (30.4%) 26 (21.1%) 19 (14.7%)
11–19 61 (13.3%) 3 (2.4%) 11 (8.5%)
20 or more 35 (7.6%) 1 (0.8%) 5 (3.9%)
448 (98.0%) 120 (99.2%) 125 (98.4%) 0.76 (2) 0.68
*p-value is significant
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mentioned a number of popular products including Adco-
dol® (n = 66, 53.2%) and Lenadol® (n = 24, 19.4%) and also
mentioned cough and cold syrups such as Benylin with
Codeine® (n = 27, 21.8%) and Broncleer with Codeine®
(n = 21, 16.9%). In the UK, Co-codamol (n = 86, 66.7%),
Solpadeine® (n = 82, 63.6%) and Nurofen Plus® (n = 76, 58.
9%) were the most popular products (see Fig. 1).
The majority of participants saw codeine misuse as a
public health issue, with the highest proportion of partici-
pants in South Africa reporting codeine misuse as a prob-
lem (n = 91, 74.0%). Almost two-thirds of participants in
Ireland (n = 302, 65.1%) and just over half reporting this in
the UK (n = 75, 58.1%) viewed it as a public health issue.
These proportions were significantly different across the
three countries (X2 = 7.6 (2), p = 0.02).
Respondents across all three countries reported that a
low to medium amount of codeine sold in their pharmacies
is misused, with no significant differences across South
Africa, Ireland and the United Kingdom.
The majority of participants reported that they had not
received any kind of specialist training in substance use
issues (Table 4). In Ireland, only 69 (15.0%) had received
training, which was significantly lower than in South Africa
(n = 31, 25.2%) and the UK (n = 32, 24.8%) (X2 = 10.9(2),
p = 0.004). Most of the participants reported a further need
for training and education (Ireland: n = 284, 61.5%, South
Table 3 Pharmacy perspectives of codeine as a popular product or problem and cross-country comparisons
Ireland (n = 464) (n, %) South Africa (n = 123) (n, %) UK (n = 129) (n, %) Test statistic χ2(df) p-value
Most popular product
Cough/cold syrup 8 (1.8%) 34 (27.9%) 1 (0.8%) 122.7 (2) < 0.001*
Combination medication 448 (98.2%) 88 (72.1%) 128 (99.2%)
Missing 10 1 0
Codeine as significant health problem 302 (65.1%) 91 (74.0%) 75 (58.1%) 7.6 (2) 0.02*
Amount of codeine misused
Low 177 (38.2%) 40 (32.5%) 59 (45.7%)
Medium 204 (44.9%) 56 (46.3%) 59 (45.7%)
High 73 (16.1%) 25 (20.7%) 10 (7.8%)
Missing 12 2 1 2.9 0.09
*p-value is signficant
Fig. 1 Most commonly used codeine-containing products reported by pharmacy staff across three countries
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Africa: n = 87, 71.3%, UK: n = 81, 62.8%) with no country
differences (X2 = 4.1(2), p = 0.13).
Participants were also asked if education and support ma-
terials on substance use would be useful for pharmacy
customers and the general public (Table 4). There were sig-
nificant inter-country differences, with the highest propor-
tion expressing need for such public education in South
Africa (n = 113, 91.1%), followed by Ireland (n = 393, 85.4%)
, and then the UK (n = 100, 78.1%) (X2 = 8.5(2), p = 0.01).
When asked about existing risk management systems
(that flags customers who may be abusing codeine, 51.6%
of participants in the UK (n = 66) reported that this system
exists in their country. A similar proportion (n = 60, 50.4%)
in South Africa reported having a risk management system,
while in Ireland this proportion was significantly lower
(n = 177, 39.0%) (X2 = 9.5(2), p = 0.009). The majority of
participants were willing to participate in a centralised
system that monitors the provision of codeine products
within pharmacies (Ireland: n = 334, 71.9%; South Africa:
n = 95, 77.2%; UK: n = 107, 83.0%). There were no
significant country differences (X2 = 5.3(2), p = 0.07).
Finally, significantly more pharmacy staff in the UK
(n = 75, 58.1%) than in Ireland (n = 191, 41.2%) or South
Africa (n = 51, n = 41.5%) reported that they believe that
the current level of codeine control in their jurisdiction
is high enough (X2 = 12.0(2), p = 0.002).
Discussion
Most pharmacy studies investigating the misuse of
pharmaceutical opioids have focused on stronger opioids
as opposed to weaker opioids like codeine which are
frequently sold over the counter as combination phar-
maceuticals. This study is one of the first in these coun-
tries conducted with pharmacy staff solely on the topic
of codeine use and misuse, as well as the different coun-
tries’ response to codeine misuse. The findings indicate
that the misuse of codeine is seen as a significant public
health issue by pharmacy staff, and also indicated a need
for training in the field of substance use in general.
The majority of participants reported that from their
experience, a medium to high amount of codeine
provided at pharmacies is misused by clients in all three
countries. Concerns from pharmacists around the mis-
use of codeine-containing products in general by their
profession has also been identified in other studies con-
ducted with pharmacists about the abuse of medication
[9, 15, 17, 21, 24–27] with the results of a recent Scot-
tish study finding that pharmacists reported codeine-
containing products to be the frequently abused form of
OTC medication [28]. Coupled with this, participants
admitted to gaps in their training on how to identify and
address codeine misuse and expressed a willingness to
be trained, particularly in monitoring systems. However,
findings around the control of codeine were equivocal.
A number of significant inter-country differences were
noted, indicating perhaps different methods of dealing with
misuse. For example, while all three countries discussed the
popularity of codeine-containing combination products,
only South African pharmacy staff reported that codeine-
containing syrups were popular. There is recent evidence
that codeine-containing syrups are increasingly popular
with young people especially in relation to youth culture
[29]. Elsewhere user preferences have been for codeine-
containing tablets [2, 29]. This is partly because cough
syrup that contains codeine is less available in the UK
and Ireland in comparison to South Africa [29].
Another inter-country difference noted was the pro-
portion of participants who reported that their country
had an existing risk management system in place in
pharmacies that could be used to limit drug-related
harms. In this regard, the highest proportion of partici-
pants in the UK reported a willingness to participate in
such a monitoring system.
The use of real-time reporting to monitor medications
including opiates exists in various countries including
the USA, Canada and Australia [2, 30] and has also been
recommended based on the findings of a recent scoping
review of codeine [31]. This review suggested that pre-
scription drug monitoring through an online system for
prescriptions, combined with real time systems for both
OTC and prescription codeine-containing products
should be developed which could be used in pharmacies.
Table 4 Existing resources for pharmacy staff and cross-country differences
Ireland (n = 464)
(n, %)
South Africa (n = 123)
(n, %)
UK (n = 129)
(n, %)
Test statistic
χ2(df)
p
Specialist addiction training 69 (15.0%) 31 (25.2%) 32 (24.8%) 10.9 (2) 0.004*
Need for training and education 284 (61.5%) 87 (71.3%) 81 (62.8%) 4.1 (2) 0.13
Need for public education 393 (85.4%) 113 (91.1%) 100 (78.1%) 8.5 (2) 0.01*
Existing risk management system 177 (39.0%) 60 (50.4%) 66 (51.6%) 9.5 (2) 0.009*
Willingness to participate in centralized monitoring
system
333 (74.5%) 96 (80.0%) 107 (83.6%) 5.3 (2) 0.07
Belief that current level of codeine control in jurisdiction is
high enough
192 (42.0%) 50 (41.0%) 75 (58.6%) 12.0 (2) 0.002*
*p-value is signficant
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It is suggested that such systems may be useful to track
and monitor levels of dispensing and reduce inappropriate
prescribing. It is also recommended that they could be
used to reduce ‘user shopping’ at multiple prescribers and
pharmacies and thereby aid to reduce adverse events such
as overdose [32]. This is possibly an innovative approach
to dealing with codeine misuse.
The use of real-time monitoring systems can help to
ensure that patients who present with genuine thera-
peutic need receive OTC codeine-based products. This
type of system can also assist in identifying possible mis-
use by flagging consumers that purchase large quantities
of codeine-based products. This has been effective for
other products such as pseudoephedrine in Australia,
where the Project STOP programme is implemented
[32], which assists pharmacist in making decisions to
dispense of products containing pseudoephedrine or not.
In South Africa, such a surveillance system was devel-
oped, known as the Codeine Care Initiative [33], which
consists of tagging codeine-containing medication in
combination with a secure central database to monitor
these purchases across the country. However, it has been
put on hold. Australia implemented a similar voluntary
real-time monitoring program for OTC codeine (Med-
sASSIST) briefly prior to the decision to up schedule all
codeine-containing products to prescription only [34].
Since tracking customers that purchase OTC products
containing codeine can be challenging, the study findings
also support the consideration of alternative approaches
to reduce misuse and dependence on OTC codeine-
containing products. These focus on comprehensive care
practices within pharmacies including detecting and asses-
sing consumer codeine misuse, the provision of informa-
tion around risk of dependence and associated harms to
clients, and how to prevent adverse effects [3].
Another finding from the current study is that partici-
pants reported that pharmacy staff lacked training, but
wanted specific training around substance use issues,
including codeine. Previous studies have recommended that
increased practice emphasis on specific pharmacist and
counter staff training in addiction, mental health and com-
munication or conflict resolution skills should be consid-
ered [9, 20, 24, 35–37]. In addition, pseudo-patron visits
[37] as a training tool in adherence to standards of practice
can provide immediate feedback, and result in positive
changes in quality of service in pharmacy practice [38, 39].
Limitations
One of the limitations of the current study was the low re-
sponse rate in both South Africa and the UK. In Ireland,
the authors had established a relationship with a key staff
member at the PSI, which led to the survey being sent out
by the professional body first hand, and also allowed for
intermittent reminders to be sent out to complete the
survey. The lower response rate was, however, not from the
lack of trying on the authors’ part in the other two coun-
tries. In the UK, the General Pharmaceutical Council only
provides physical addresses of pharmacies for research pur-
poses. The South African Pharmacy Council was willing to
put a link in their newsletter that went out, but not send
the questionnaire to registered pharmacy staff. It must be
noted that paper questionnaires could have been posted to
the pharmacies in the UK and Ireland, but since this was a
web-based survey it would not have been advisable to use
a mixed-methods approach. As mentioned earlier, one of
the limitations was the low response rate in South Africa
and the UK. It is possible that future studies be conducted
that are only paper-based to ascertain whether this will
lead to a larger sample size, and greater generalisation.
Due to this small size and since the study was only
conducted in three countries, we acknowledge that it is
not possible to generalise the current findings to the
general pharmacy community in a) these three countries
or b) other countries beyond the three included in the
sample. Despite this, the study still offers key insights
into the comparable experiences of pharmacy in dealing
with the public health issue of codeine misuse.
Conclusion
Misuse of opioid analgesics is an emergent global public
health concern. This study represents the first attempt
to compare pharmacist staff perceptions and experiences
across three distinct regulatory regimes providing OTC
and prescription codeine. Similar to previous studies in
Australia and the UK [17, 20], the response to patient
misuse of codeine is a challenge for community pharma-
cies. Training needs warrant consideration and develop-
ment in order for pharmacy staff to educate patients,
and intervene and support those experiencing problem-
atic codeine use. Risk management and surveillance sys-
tems equally warrant development and buy in from
regulatory bodies and the retail sector, and should be
evaluated as suggested by Shard et al. [40].
Acknowledgements
We would specifically like to thank the following pharmacy staff who
assisted with data entry and verification while they were on secondment:
Mariam Deldar, Jillian Glynn, Julie Haughey, Christine Pyke.
Funding
The research leading to these results has received funding from the
European Community’s Seventh Framework Programme FP7/2007–2013
under grant agreement no 611736.
Availability of data and materials
The datasets supporting the conclusion of this study are available by
contacting the first author.
Authors’ contributions
All authors contributed to the design of the online questionnaire. PM and
RH provided technical assistance on the questionnaire, and contributed to
the literature review. TC and CP analyzed and interpreted the data and TC
drafted the manuscript. MVC contributed to the literature review and
Carney et al. Substance Abuse Treatment, Prevention, and Policy  (2018) 13:12 Page 7 of 8
discussion. JW provided guidance on the manuscript and strong editorial
comments. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This research project was reviewed by the South African Medical Research
Council, Waterford Institute of Technology and Kings College London, and ethics
approval was obtained. Proof of ethics approval can be provided upon request.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Alcohol, Tobacco and Other Drug Research Unit, South African Medical
Research Council, Francie Van Zijl Drive, Parow, South Africa. 2Department of
Psychiatry and Mental Health, University of Cape Town, Cape Town, South
Africa. 3School of Health Sciences, Waterford Institute of Technology,
Waterford, Ireland. 4Department of Psychiatry, Stellenbosch University,
Stellenbosch, South Africa. 5CARA Pharmacy, Waterford, Ireland. 6Weldricks
Pharmacy, Sheffield, UK. 7Public Health Policy, Liverpool John Moore’s
University, Liverpool, UK.
Received: 19 December 2017 Accepted: 14 March 2018
References
1. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European
Union: a systematic review of the literature. Eur Addict Res. 2012;18(5):228–45.
2. UNODC. The non medicinal use of prescription drugs. Vienna: United
Nations; 2011.
3. Van Hout M, Norman I. Over the counter codeine misuse:
recommendations for detection and reduction of risk in community
pharmacies. Int J Drug Policy. 2016;27:17–22.
4. INCB. Narcotic drugs - yellow list. International Narcotics Control Board:
Austria; 2011.
5. Derry S, Karlin SM, Moore R. Single dose oral ibuprofen plus codeine for acute
postoperative pain in adults. Cochrane Database Sys Rev. 2015;2:CD010107.
6. Nielsen S, Van Hout MC. Over-the-counter codeine –from therapeutic use to
dependence, and the grey areas in between. Curr Top Behav Neurosci.
2016;34:59–75.
7. Van Hout MC. Doctor shopping and pharmacy hopping: practice
innovations relating to codeine. Drug Alcohol Today. 2014;14(4):219–34.
8. Nielsen S, Cameron J, Pahoki S. Over the counter codeine dependence.
Turning Point Alcohol and Drug Centre: Victoria, Australia; 2010.
9. Cooper R. ‘Respectable addiction’ - a qualitative study of over the counter
medicine abuse in the UK. London: Pharmacy Practice Research Trust; 2011.
10. Cooper RJ. Over-the-counter medicine abuse: a review of the literature. J
Subs Use. 2013;18:82–107.
11. Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of
over-the-counter nicotine replacement. Tob Control. 2003;12(1):21–7.
12. Wazaify M, Shields E, Hughes CM, McElnay JC. Societal perspectives on over-
the-counter (OTC) medicines. Fam Pract. 2005;22(2):170–6.
13. Fleming GF, McElnay JC, Hughes CM. Development of a community
pharmacy-based model to identify and treat over the counter drug abuse/
misuse: a pilot study. Pharm World Sci. 2004;26:282–8.
14. Carney T, Wells J, Bergin M, Dada S, Foley M, McGuiness P, et al. A
comparative community pharmacists’ views on the nature and
management of over-the-counter (OTC) and prescription codeine misuse in
three regulatory regimes: Ireland, South Africa and the United Kingdom. Int
J Ment Health Addict. 2016;14:351–9.
15. Cooper R. ‘I can’t be an addict. I am.’ Over-the-counter medicine abuse: a
qualitative study. BMJ Open. 2013;3:e002913.
16. Dobbin M, Tobin CL. Over-the-counter ibuprofen/codeine analgesics:
misuse and harm. Drugs Policy and Services Branch Department of Human
Services: Melbourne; 2008.
17. Pates R, McBride A, Li S, Ramadan R. Misuse of over-the-counter medicines:
a survey of community pharmacies in a South Wales health authority.
Pharm J. 2002;268:179–82.
18. Nielsen S, Cameron J, Lee N. Characteristics of a non-treatment seeking
sample of over-the-counter codeine users: implications for intervention and
prevention. J Opioid Manag. 2011;7(5):363–70.
19. Foley M, Harris R, Rich E, Rapca A, Bergin M, Norman I, et al. The availability
of over-the-counter codeine medicines across the European Union. Public
Health. 2015;129:1465–70.
20. McAvoy BR, Dobbin MD, Tobin CL. Over-the-counter codeine analgesic
misuse and harm: characteristics of cases in Australia and New Zealand. N Z
Med J. 2011;124(1346):29–33.
21. Hamer AM, Spark MJ, Wood PJ, Roberts E. The upscheduling of
combination analgesics containing codeine: the impact on the practice of
pharmacists. RSAP. 2014;10(4):669–78.
22. Dada S, Harker Burnhams N, Van Hout MC, Parry CDH. Codeine misuse and
dependence in South Africa-learning from substance use treatment
admissions. SAMJ. 2015;105(9):776–9.
23. Parry C, Deluca P, Cooper R, Van Hout MC. Do we have sufficient
information to optimally inform regulatory or other policy decisions about
medications containing codeine? Addiction. 2015;110(10):1690–2.
24. Cooper R. Surveillance and uncertainty: community pharmacy responses to over
the counter medicine abuse. Health Soc Care Community. 2013;21(3):254–62.
25. MacFayden L, Eadie D, McGowan T. Community pharmacists’ experience of
over-the-counter medicine misuse in Scotland. J R Soc Promo Health. 2001;
121(3):185–92.
26. Matheson C, Bond C, Pitcairn J. Misuse of over-the-counter medicines from
community pharmacies: a population survey of Scottish pharmacists. Pharm
J. 2002;269:66–8.
27. Reed K, Bond A, Witton J, Cornish R, Hickman M, Strang J. The changing use
of prescribed benzodiazepines and z-drugs and of over-the-counter
codeine-containing products in England: a structured review of published
English and international evidence and available data to inform
consideration of the extent of dependence and harm. In: National
Addiction Centre KCL, and School of Social and Community Medicine,
University of Bristol, editor. London: Kings College London; 2011.
28. Wright J, Bond CM, Robertson HD, Matheson C. Changes in over-the-
counter drug misuse over 20 years: perceptions from Scottish pharmacists.
J. Public Health. 2016;38(4):793–9.
29. Van Hout MC, Rich E, Dada S, Bergin M. Codeine is my Helper: A qualitative
study of pharmacy access and codeine misuse in South Africa. Qual Health
Res. 2015; ahead of print
30. Shand F, Campbell G, Hall W, Lintzeris N, Cohen M, Degenhardt L. Real-time
monitoring of schedule 8 medicines in Australia: evaluation is essential. Med
J Aus. 2013;198(2):80–1.
31. Bergin M, Norman I, Foley M, Harris R, Rapca A, Rich E, et al. Practice
implications and recommendations for managing codeine misuse and
dependence. Acta Pharma. 2015;65:351–64.
32. Van Hout M, Bergin M, Foley M, Rich E, Rapca A, Harris R, et al. A scoping
review of codeine use, misuse and dependence, final report. 2014.
33. Le Roux K. Marketing of CPS. SAPJ. 2013;80(5):43–7.
34. Haggan M. Year in review: Codeine: An unscheduled dilemma. AJP. 2017;
98(1168):18.
35. Sheridan J, Butler R. “They’re legal so they’re safe, right?” what did the legal
status of BZP-party pills mean to young people in New Zealand? Int J Drug
Policy. 2010;21(1):77–81.
36. Phokeo V, Sproule B, Raman-Wilms L. Community Pharmacists’ attitudes
toward and professional interactions with users of psychiatric medication.
Psychiatr Serv. 2004;55(12):1434–6.
37. Berger K, Eickhoff C, Schulz M. Counselling quality in community
pharmacies: implementation of the pseudo customer methodology in
Germany. J Clin Pharm Ther. 2005;30:45–57.
38. Benrimoj SI, Gilbert A, Quintrell N, Neto AC. Non-prescription medicines: a
process for standards development and testing in community pharmacy.
Pharm World Sci. 2007;29(4):386–94.
39. Benrimoj SI, Gilbert AL, de Almeida Neto AC, Kelly F. National
implementation of standards of practice for non-prescription medicines in
Australia. Pharm World Sci. 2009;31(2):230–7.
40. Agnich LE, Stogner JM, Miller BL, Marcum CD. Purple drank prevalence and
characteristics of misusers of codeine cough syrup mixtures. Addict Behav.
2013;38(9):2445–9.
Carney et al. Substance Abuse Treatment, Prevention, and Policy  (2018) 13:12 Page 8 of 8
